Results of a clinical trial that administered blood plasma from donors, age 18 to 25 years, into individuals with Parkinson's disease resulted in significant improvements in neurologic assessments.
After 3 months, patients showed improvements in motor examinations (19.2%); mentation, behavior, and mood (12.9%); activities of daily living (7.9%); and complications from therapy (50%). Symptoms including dyskinesia and changes in facial expression, speech, handwriting, rigidity, and falling all showed improvement directly attributable to the young plasma.
The randomized, double-blind, placebo-controlled trial evaluated the efficacy of the plasma (NuPlasma young Fresh Frozen Plasma; NuPlasma, San Marcos, TX) in 19 patients (9 were given young plasma; 10 were given placebo). Patients were intravenously administered 25 mL/kg of the plasma in 2 doses over 3 days.The investigation continued to the point at which the plasma was no longer in circulation, yet continued to show a residual benefit.
Jessica M. Baker, MD
Rachana Gandhi Mehta, MD; Vanessa Baute Penry, MD; and Herbert Lloyd Bonkovsky, MD
Ryan Verity, MD; Andrew Kirk, MD, FRCPC; and Gary Hunter, MD, FRCPC, CSCN(EEG)